



**Formulary Updates  
August-September 2019**

CenCal Health has made several changes to our Formulary based on clinical review, provider interest, cost and utilization analysis. All of the changes represent development and growth of our current Formulary thus giving more choices to the prescribing physician. The changes are represented in summary on the chart below.

<b>Drug</b>	<b>Class</b>	<b>Formulary Status</b>	<b>Additional Information</b>	<b>Implementation Date</b>
<b>Formulary Additions/Deletions</b>				
Levocetirizine 5mg Tablet (Generic Xyzal)	Antihistamines - 2nd Generation	Formulary		8/1/2019
Pregabalin 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, and 300mg Capsules (Generic Lyrica)	Seizure Disorder	Formulary: Quantity Limit	Restriction: Removed Step Therapy	9/1/2019
Lidocaine 5% Patches (Generic Lidoderm)	Antipruritics and Local Anesthetics	Formulary: Quantity Limit	Restriction: Quantity limit of #30 patches for a 30 -day supply	9/1/2019
Hyoscyamine 0.125mg Tablet	Upper Gastrointestinal Disorders - Spastic Disease	Formulary: Step Therapy	Restriction: Step Therapy through Dicyclomine 10mg or 20mg capsule	9/1/2019